Cidara Therapeutics (FRA:20D0) ROCE % : -156.73% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cidara Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2024 was -156.73%.

Cidara Therapeutics ROCE % Historical Data

The historical data trend for Cidara Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics ROCE % Chart

Cidara Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-223.42

-137.17

-149.52

-920.57

-213.62

Cidara Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-248.00	-	-73.32	-54.39	-156.73

Cidara Therapeutics ROCE % Calculation

Cidara Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-168.177	/	( ( (61.467 - 61.822)	+	(205.13 - 47.324) )	/ 2 )
	=	-168.177	/	( (-0.355	+	157.806)	/ 2 )
	=	-168.177	/	78.7255
	=	-213.62 %

Cidara Therapeutics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-206.976	/	( ( (146.26 - 39.949)	+	(205.13 - 47.324) )	/ 2 )
	=	-206.976	/	( ( 106.311	+	157.806 )	/ 2 )
	=	-206.976	/	132.0585
	=	-156.73 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Cidara Therapeutics (FRA:20D0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cidara Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CDTX:USA 20D0:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines